|
Mar 8
|
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
|
|
Jan 22
|
Should You Invest in Immunovant (IMVT)?
|
|
Jan 19
|
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
|
|
Jan 13
|
Immunovant Inc CFO Eva Barnett Sells 3,515 Shares
|
|
Dec 26
|
Immunovant (IMVT) Rose on Positive Clinical Trial
|
|
Dec 21
|
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
|
|
Dec 21
|
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data
|
|
Dec 21
|
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
|
|
Dec 20
|
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
|
|
Dec 20
|
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
|
|
Dec 19
|
11 Stocks Insiders and Billionaires Are Crazy About
|
|
Dec 1
|
Here’s Why Immunovant (IMVT) Outperformed in Q3
|
|
Nov 29
|
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
|
|
Nov 28
|
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
|
|
Nov 28
|
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
|
|
Jul 3
|
Top Growth Stocks for July 2023
|
|
Jul 1
|
Top Stocks for July 2023
|
|
Jun 29
|
Q4 2023 Roivant Sciences Ltd Earnings Call
|